RVM V003
Alternative Names: RVM-V003Latest Information Update: 10 Mar 2023
Price :
$50 *
At a glance
- Originator RVAC Medicines
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 20 Feb 2023 Health Sciences Authority of Singapore approves clinical trial application for RVM V003 in COVID-2019 infections
- 20 Feb 2023 RVAC Medicines files a clinical trial application with the Health Sciences Authority in Singapore for COVID-2019 infections prior to February 2023
- 20 Feb 2023 RVAC Medicines plans a phase Ib trial for COVID-2019 infections (Prevention) in Singapore in February 2023 (Parenteral)